IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
IPO Year: 2014
Exchange: NASDAQ
Website: iradimed.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/12/2023 | $50.00 | Buy | Lake Street |
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "Being recognized by Fortune as one of the 100 Fastest Growing Companies for 2024 is a tremendous honor," said Roger Susi, President and Chief Executive Officer of the Company. "This achievement underscores our team's pas
Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail
WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference. Iradimed's CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on October 9, 2024. About IRADIMED CORPORATIONIRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatib
WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference. Iradimed management will host one-on-one meetings between company management and investors at the Lake Street 8th Annual Best Ideas Growth "Big 8" Conference at the Yale Club in New York on September 12, 2024. About IRADIMED CORPORATIONIRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manuf
Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the third quarter of 2024, payable on August 30, 2024. WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Com
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa6da8f185c0d4199a6c370fbe9fba158. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim
WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol "IRMD." Stockholders are not required to take any action due to the uplisting. Roger Susi, President and Chief Executive Officer of Iradimed, expressed his enthusiasm about this significant achievement: "Iradimed's advancement to the Nasdaq Global Market is a notable accomplishment for our company and reflects Iradimed's continued gro
Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa8e7a7f6a1a54f62b666af525d8cefcc. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti
Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00
WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,
Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously
144 - IRADIMED CORP (0001325618) (Subject)
10-Q - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
10-Q - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
8-K - IRADIMED CORP (0001325618) (Filer)
144 - IRADIMED CORP (0001325618) (Subject)
8-K - IRADIMED CORP (0001325618) (Filer)
ARS - IRADIMED CORP (0001325618) (Filer)
Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail
Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the third quarter of 2024, payable on August 30, 2024. WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Com
Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa6da8f185c0d4199a6c370fbe9fba158. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim
Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI
WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa8e7a7f6a1a54f62b666af525d8cefcc. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti
Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023. Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, compared to the same period in 2022. WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three m
WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIc7cd4e26433141619fd5dc96c9970143.Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim
WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12, 2024, to shareholders of record at the close of business on December 22, 2023. Dividend history to date:At the end of 2021, the Company's Board concluded that the strong financial performance being posted warranted a dividend to return to shareholders some of the ava
Reports record revenue of $16.5 million for the third quarter of 2023.GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022. WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that ar
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
4 - IRADIMED CORP (0001325618) (Issuer)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
SC 13G/A - IRADIMED CORP (0001325618) (Subject)
IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol "IRMD." Stockholders are not required to take any action due to the uplisting.
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.88 percent. This is a 20 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $17.598 million which beat the analyst consensus estimate of $17.130 million by 2.73 percent. This is a 13.72 percent increase over sales of $15.475 million the same period last year.
Roth MKM analyst Jason Wittes reinstates iRadimed (NASDAQ:IRMD) with a Buy and announces $65 price target.
- SEC Filing
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.40 by 2.5 percent. This is a 21.88 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $17.45 million which beat the analyst consensus estimate of $17.33 million by 0.70 percent. This is a 17.42 percent increase over sales of $14.86 million the same period last year.
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. • ArcelorMittal (NYSE:MT) is estimated to report quarterly loss at $2.16 per share on revenue of $15.42 billion. • AstraZeneca (NASDAQ:AZN) is expected to report quarterly earnings at $0.79 per share on revenue of $12.09 billion. • Lightspeed Commerce (NYSE:LSPD) is estimated to report quarterly earnings at $0.05 per share on revenue of $235.86 million. • Aurora Cannabis (NASDAQ:ACB) is likely to report quarterly loss at $0.01 per share on revenue of $63.39 million. • Brookfield (NYSE:BN) is projected to report quarterly earnings a